Granted Patent
B2
US 8,058,240 · App. 12/296,446 · Granted Nov 15, 2011
Biological active ligands of melanocortin receptors
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are novel ligands based on an AGRP template that can rescue endogenous melanocortin agonist and/or antagonist dysfunction at MCR polymorphisms. In particular, the present invention provides novel synthetic ligands based on AGRP templates that can rescue endogenous melanocortin agonist dysfunction at MC4R polymorphisms to treat children and adults with these mutations and increase their quality of life.
Claims (2)
1. An isolated ligand that is biologically active at melanocortin receptors having a sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:68.
2. A composition comprising a ligand having a sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:68, or is a salt thereof.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Oct 13, 2016
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040340/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 11, 2009
From: HASKELL-LUEVANO, CARRIE
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 022239/0867 →
Continuity (2)
Provisional Application
60792703
· Apr 18, 2006